Known targets — ChEMBL curated mechanism
ACHEADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3APH1AAPH1BCHRM2CHRM3EZH2GRIN2AHTR1AHTR1BHTR1DHTR1FHTR3ANCSTNP2RY12PSEN1PSEN2PSENENSIGMAR1SLC6A2SLC6A3SLC6A4
The experimentally established mechanism targets of Bromide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 6/20 | 0.49 |
| ▸ | DPP8 | Q6V1X1 | 2/20 | 0.49 |
| ▸ | DPP9 | Q86TI2 | 2/20 | 0.49 |
| ▸ | XIAP | P98170 | 3/20 | 0.43 |
| ▸ | MLX | Q9UH92 | 1/20 | 0.41 |
| ▸ | FAP | Q12884 | 2/20 | 0.40 |
| ▸ | DPP7 | Q9UHL4 | 2/20 | 0.40 |
| ▸ | PREP | P48147 | 2/20 | 0.40 |
| ▸ | ELANE | P08246 | 6/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2768336 | 0.99 | DPP4 (0.50) | DPP4DPP8DPP9XIAPMLX | |
| SCHEMBL30052033 | 0.88 | ACE (0.51) | DPP4DPP8DPP9XIAPMEN1 | |
| SCHEMBL14953540 | 0.86 | DPP4 (0.46) | DPP4DPP8DPP9XIAPMLX | |
| SCHEMBL13380009 | 0.86 | XIAP (0.47) | DPP4DPP8DPP9XIAPMLX | |
| Bromide SCHEMBL1509597 | 0.84 | DPP4 (0.42) | DPP4DPP8DPP9XIAPMLX | |
| SCHEMBL29378104 | 0.84 | ACE (0.47) | DPP4DPP8DPP9XIAPMEN1 | |
| Bromide SCHEMBL3164359 | 0.84 | XIAP (0.47) | DPP4DPP8DPP9XIAPFAP | |
| SCHEMBL17305252 | 0.83 | DPP4 (0.52) | DPP4DPP8DPP9ELANE | |
| SCHEMBL13379994 | 0.83 | XIAP (0.49) | DPP4DPP8DPP9XIAPMLX | |
| SCHEMBL13073333 | 0.82 | DPP4 (0.49) | DPP4DPP8DPP9XIAPMLX |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 61 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1675578-B9 | INHIBITORS OF GLUTAMINYL AND GLUTAMATE CYCLASES FOR THE TREATMENT OF THE NEURODEGENERATIVE DISEASES FBD AND FDD | PROBIODRUG AG (DE) | 2014-06-25 | — | — | EP | claimed |
| US-8470781-B2 | Use of effectors of glutaminyl and glutamate cyclases | PROBIODRUG AG (DE) | 2013-06-25 | — | — | US | claimed |
| EP-1675578-B1 | INHIBITORS OF GLUTAMINYL AND GLUTAMATE CYCLASES FOR THE TREATMENT OF THE NEURODEGENERATIVE DISEASES FBD AND FDD | PROBIODRUG AG (DE) | 2013-05-22 | — | — | EP | claimed |
| EP-2289498-A1 | Use of inhibitors of glutaminyl clyclase | Probiodrug AG (DE) | 2011-03-02 | — | — | EP | claimed |
| EP-1620082-B9 | MEDICAL USE OF INHIBITORS OF GLUTAMINYL AND GLUTAMATE CYCLASES FOR TREATING ALZHEIMER'S DISEASE AND DOWN SYNDROME | PROBIODRUG AG (DE) | 2010-08-25 | — | — | EP | claimed |
| EP-2206496-A1 | Medical use of inhibitors of glutaminyl and glutamate cyclases | Probiodrug AG (DE) | 2010-07-14 | — | — | EP | claimed |
| EP-1620082-B1 | MEDICAL USE OF INHIBITORS OF GLUTAMINYL AND GLUTAMATE CYCLASES FOR TREATING ALZHEIMER'S DISEASE AND DOWN SYNDROME | PROBIODRUG AG (DE) | 2010-04-21 | — | — | EP | claimed |
| US-7608577-B2 | Peptidyl ketones as inhibitors of DPIV | OSI PHARMACEUTICALS, INC. (US) | 2009-10-27 | — | — | US | claimed |
| US-20090149394-A1 | USE OF EFFECTORS OF GLUTAMINYL AND GLUTAMATE CYCLASES | PROBIODRUG AG (DE) | 2009-06-11 | — | — | US | claimed |
| US-7462599-B2 | Use of effectors of glutaminyl and glutamate cyclases | PROBIODRUG AG (DE) | 2008-12-09 | — | — | US | claimed |
| EP-1961416-A1 | Medical use of inhibitors of glutaminyl and glutamate cyclases | Probiodrug AG (DE) | 2008-08-27 | — | — | EP | claimed |
| US-7381537-B2 | Use of inhibitors of glutaminyl cyclases for treatment and prevention of disease | PROBIODRUG AG (DE) | 2008-06-03 | — | — | US | claimed |
| US-20060189523-A1 | Use of effectors of glutaminyl and glutamate cyclases | PROBIODRUG AG (DE) | 2006-08-24 | — | — | US | claimed |
| EP-1434792-A2 | PEPTIDYL KETONES AS INHIBITORS OF DPIV | Probiodrug AG (DE) | 2004-07-07 | — | — | EP | claimed |
| US-20030148961-A1 | Peptidyl ketones as inhibitors of DPIV | PROSIDION LIMITED (GB) | 2003-08-07 | — | — | US | claimed |
| WO-2003033524-A2 | PEPTIDYL KETONES AS INHIBITORS OF DPIV | PROBIODRUG AG (DE) | 2003-04-24 | — | — | WO | claimed |
| EP-1675578-B9 | INHIBITORS OF GLUTAMINYL AND GLUTAMATE CYCLASES FOR THE TREATMENT OF THE NEURODEGENERATIVE DISEASES FBD AND FDD | PROBIODRUG AG (DE) | 2014-06-25 | — | — | EP | disclosed |
| US-8470781-B2 | Use of effectors of glutaminyl and glutamate cyclases | PROBIODRUG AG (DE) | 2013-06-25 | — | — | US | disclosed |
| US-20040224875-A1 | Inhibitors of glutaminyl cyclase | PROBIODRUG AG (DE) | 2004-11-11 | — | — | US | disclosed |
| WO-2004031374-A2 | SECONDARY BINDING SITE OF DIPEPTIDYL PEPTIDASE IV (DP IV) | PROSIDION LTD. (GB) | 2004-04-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030148961-A1 | Peptidyl ketones as inhibitors of DPIV | GLS, SLC5A1, BCKDK | DPP4 60/4885DPP8 170/4885DPP9 149/4885 |
| US-20060189523-A1 | Use of effectors of glutaminyl and glutamate cyclases | GLS, GLUL, GLS2 | DPP4 1981/4885DPP8 3636/4885DPP9 2668/4885 |
| US-20090149394-A1 | USE OF EFFECTORS OF GLUTAMINYL AND GLUTAMATE CYCLASES | GLS, GLUL, GLS2 | DPP4 1981/4885DPP8 3636/4885DPP9 2668/4885 |
| US-20040224875-A1 | Inhibitors of glutaminyl cyclase | GLS2, GLS, GLUL | DPP4 2056/4885DPP8 2739/4885DPP9 1376/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.